Halper Sadeh LLC Investigates BioVie Executives' Fiduciary Duties
- Legal Investigation Launched: Halper Sadeh LLC is investigating whether certain officers and directors of BioVie Inc. breached their fiduciary duties to shareholders, potentially leading to governance reforms.
- Shareholder Rights Protection: Long-term shareholders of BioVie may seek corporate governance reforms, fund returns, or court-approved financial incentive awards, enhancing their rights and interests.
- Transparency Improvement: Shareholder involvement can improve the company's policies, practices, and oversight mechanisms, promoting more transparent and effective management, thereby increasing shareholder value.
- Legal Fee Arrangement: Halper Sadeh LLC will handle the case on a contingent fee basis, meaning shareholders will not be responsible for out-of-pocket legal fees or expenses, reducing the financial burden of participation.
Trade with 70% Backtested Accuracy
Analyst Views on BIVI
About BIVI
About the author
Halper Sadeh LLC Investigates BioVie Executives' Fiduciary Duties
- Legal Investigation Launched: Halper Sadeh LLC is investigating whether certain officers and directors of BioVie Inc. breached their fiduciary duties to shareholders, potentially leading to governance reforms.
- Shareholder Rights Protection: Long-term shareholders of BioVie may seek corporate governance reforms, fund returns, or court-approved financial incentive awards, enhancing their rights and interests.
- Transparency Improvement: Shareholder involvement can improve the company's policies, practices, and oversight mechanisms, promoting more transparent and effective management, thereby increasing shareholder value.
- Legal Fee Arrangement: Halper Sadeh LLC will handle the case on a contingent fee basis, meaning shareholders will not be responsible for out-of-pocket legal fees or expenses, reducing the financial burden of participation.
New to The Street Broadcasts Show #716 Featuring SDST and Others
- Broadcast Timing: New to The Street will air Show #716 tonight at 6:30 PM Eastern Time on Bloomberg Television, enhancing its influence in the business media landscape by showcasing various public companies.
- Company Highlights: The episode will spotlight Stardust Power Inc. (NASDAQ:SDST), BioVie Inc. (NASDAQ:BIVI), and Roadzen Inc. (NASDAQ:RDZN), showcasing innovations in critical minerals, biotechnology, and AI-driven mobility and insurance solutions, aimed at attracting investor interest.
- Celebrity Features: The show will also include special segments with Kelsey Grammer discussing his new book KAREN and Andrew Shaw introducing his nonprofit 250DAYS.ORG, emphasizing the importance of mental health awareness and recovery, thereby enhancing the program's social impact.
- International Expansion Plans: New to The Street plans to launch its international version in the MENA region on January 24, 2026, further expanding its global reach, while also preparing to launch the Spanish-language platform Nuevo En La Calle, showcasing its diversified media strategy.
BioVie Inc. Investigated for Potential Breach of Fiduciary Duties by Executives
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether executives of BioVie Inc. breached their fiduciary duties, which could impact corporate governance and shareholder rights.
- Legal Relief Options: Long-term shareholders of BioVie may seek corporate governance reforms, fund recovery, or court-approved financial incentives, aimed at enhancing company transparency and accountability.
- Importance of Participation: Shareholder involvement can improve company policies and oversight mechanisms, thereby enhancing shareholder value and increasing the effectiveness of corporate management.
- Legal Fee Arrangement: Halper Sadeh LLC will handle the case on a contingency fee basis, meaning shareholders will not incur out-of-pocket legal fees, reducing the financial burden of participation.
Biotech Stocks Fluctuate Post-Market: Delcath Gains from Buyback, BioVie and Cassava Recover
Delcath Systems' Buyback Announcement: Delcath Systems saw a 4.02% increase in after-hours trading to $8.52 following the announcement of a $25 million share repurchase program, indicating confidence in its long-term outlook.
BioVie Inc. Gains Despite No News: BioVie Inc. rose 13.39% to $1.44 in extended trading, rebounding from a decline during the regular session, with the increase attributed to speculative trading rather than new company-specific news.
Cassava Sciences' After-Hours Rally: Cassava Sciences advanced 9.17% to $2.87 after hours, recovering from a regular session drop, as investors reacted to its recent Q3 results showing a reduced net loss and significant cash reserves.
Enlivex Therapeutics' Modest Increase: Enlivex Therapeutics experienced a 4.24% rise to $0.95 in after-hours trading, despite no new developments reported on Thursday.
Participate in Biovie's Exclusive Live Investor Webinar and Q&A on December 9
Webinar Announcement: BioVie Inc. is hosting a webinar on December 9, 2025, featuring CEO Cuong Do, who will discuss the company's drug candidate bezisterim and its potential in treating neurological diseases and liver complications.
Drug Development Focus: Bezisterim targets inflammation and insulin resistance linked to Alzheimer's, Parkinson's, and Long COVID, while BIV201 is an orphan drug candidate for refractory ascites, currently in late-stage clinical development.
Market Potential: BioVie is advancing multiple late-stage clinical programs with promising safety data and significant market opportunities, positioning the company for potential value creation through upcoming milestones and partnerships.
Forward-Looking Statements: The press release includes forward-looking statements regarding the company's expectations and potential risks, emphasizing that actual results may differ from projections due to various factors.
BIOVIE UPDATE: Bragar Eagel & Squire, P.C. Investigates BioVie Inc. for Long-Term Shareholders and Urges Investors to Reach Out to the Firm
Investor Alert: Bragar Eagel & Squire, P.C. is investigating potential claims against BioVie Inc. (BIVI) for long-term stockholders who may have suffered losses between August 5, 2021, and November 29, 2023, following a class action complaint regarding breaches of fiduciary duties by the company's board.
Clinical Trial Issues: BioVie disclosed significant protocol deviations and Good Clinical Practice violations in its Phase 3 clinical trial for NE3107, leading to a 60% drop in share price after the trial failed to achieve statistical significance due to the exclusion of patients from the trial.
Halper Sadeh LLC Investigates BioVie Executives' Fiduciary Duties
- Legal Investigation Launched: Halper Sadeh LLC is investigating whether certain officers and directors of BioVie Inc. breached their fiduciary duties to shareholders, potentially leading to governance reforms.
- Shareholder Rights Protection: Long-term shareholders of BioVie may seek corporate governance reforms, fund returns, or court-approved financial incentive awards, enhancing their rights and interests.
- Transparency Improvement: Shareholder involvement can improve the company's policies, practices, and oversight mechanisms, promoting more transparent and effective management, thereby increasing shareholder value.
- Legal Fee Arrangement: Halper Sadeh LLC will handle the case on a contingent fee basis, meaning shareholders will not be responsible for out-of-pocket legal fees or expenses, reducing the financial burden of participation.
New to The Street Broadcasts Show #716 Featuring SDST and Others
- Broadcast Timing: New to The Street will air Show #716 tonight at 6:30 PM Eastern Time on Bloomberg Television, enhancing its influence in the business media landscape by showcasing various public companies.
- Company Highlights: The episode will spotlight Stardust Power Inc. (NASDAQ:SDST), BioVie Inc. (NASDAQ:BIVI), and Roadzen Inc. (NASDAQ:RDZN), showcasing innovations in critical minerals, biotechnology, and AI-driven mobility and insurance solutions, aimed at attracting investor interest.
- Celebrity Features: The show will also include special segments with Kelsey Grammer discussing his new book KAREN and Andrew Shaw introducing his nonprofit 250DAYS.ORG, emphasizing the importance of mental health awareness and recovery, thereby enhancing the program's social impact.
- International Expansion Plans: New to The Street plans to launch its international version in the MENA region on January 24, 2026, further expanding its global reach, while also preparing to launch the Spanish-language platform Nuevo En La Calle, showcasing its diversified media strategy.
BioVie Inc. Investigated for Potential Breach of Fiduciary Duties by Executives
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether executives of BioVie Inc. breached their fiduciary duties, which could impact corporate governance and shareholder rights.
- Legal Relief Options: Long-term shareholders of BioVie may seek corporate governance reforms, fund recovery, or court-approved financial incentives, aimed at enhancing company transparency and accountability.
- Importance of Participation: Shareholder involvement can improve company policies and oversight mechanisms, thereby enhancing shareholder value and increasing the effectiveness of corporate management.
- Legal Fee Arrangement: Halper Sadeh LLC will handle the case on a contingency fee basis, meaning shareholders will not incur out-of-pocket legal fees, reducing the financial burden of participation.
Biotech Stocks Fluctuate Post-Market: Delcath Gains from Buyback, BioVie and Cassava Recover
Delcath Systems' Buyback Announcement: Delcath Systems saw a 4.02% increase in after-hours trading to $8.52 following the announcement of a $25 million share repurchase program, indicating confidence in its long-term outlook.
BioVie Inc. Gains Despite No News: BioVie Inc. rose 13.39% to $1.44 in extended trading, rebounding from a decline during the regular session, with the increase attributed to speculative trading rather than new company-specific news.
Cassava Sciences' After-Hours Rally: Cassava Sciences advanced 9.17% to $2.87 after hours, recovering from a regular session drop, as investors reacted to its recent Q3 results showing a reduced net loss and significant cash reserves.
Enlivex Therapeutics' Modest Increase: Enlivex Therapeutics experienced a 4.24% rise to $0.95 in after-hours trading, despite no new developments reported on Thursday.
Participate in Biovie's Exclusive Live Investor Webinar and Q&A on December 9
Webinar Announcement: BioVie Inc. is hosting a webinar on December 9, 2025, featuring CEO Cuong Do, who will discuss the company's drug candidate bezisterim and its potential in treating neurological diseases and liver complications.
Drug Development Focus: Bezisterim targets inflammation and insulin resistance linked to Alzheimer's, Parkinson's, and Long COVID, while BIV201 is an orphan drug candidate for refractory ascites, currently in late-stage clinical development.
Market Potential: BioVie is advancing multiple late-stage clinical programs with promising safety data and significant market opportunities, positioning the company for potential value creation through upcoming milestones and partnerships.
Forward-Looking Statements: The press release includes forward-looking statements regarding the company's expectations and potential risks, emphasizing that actual results may differ from projections due to various factors.
BIOVIE UPDATE: Bragar Eagel & Squire, P.C. Investigates BioVie Inc. for Long-Term Shareholders and Urges Investors to Reach Out to the Firm
Investor Alert: Bragar Eagel & Squire, P.C. is investigating potential claims against BioVie Inc. (BIVI) for long-term stockholders who may have suffered losses between August 5, 2021, and November 29, 2023, following a class action complaint regarding breaches of fiduciary duties by the company's board.
Clinical Trial Issues: BioVie disclosed significant protocol deviations and Good Clinical Practice violations in its Phase 3 clinical trial for NE3107, leading to a 60% drop in share price after the trial failed to achieve statistical significance due to the exclusion of patients from the trial.
